CTLA4 and cardiac hypertrophy: Morphological characterization of the myocardial tissue phenotype in mice after short-term anti-CTLA-4 or anti-PD-1 treatment clearly indicates no cardiac hypertrophy with the exception of Pembrolizumab (Figure 5).